The Neotropix Clinical Advisory Board consists of four oncology department
chairman/directors, with specific expertise in thoracic oncology. Additionally,
each of the clinical advisory members has previous clinical or research
experience with oncolytic viruses, and three have prior involvement with
oncolytic virus clinical trials. The depth and breadth of experience
on this board will prove invaluable in shaping the clinical and research
strategy for our viral therapies.
A brief summary of each of the members is listed below:
Jack
Roth, M.D., MD Anderson Cancer Center
Chairman Department of Thoracic and Cardiovascular Surgery
William
G. Kaelin, Jr., M.D., Dana-Farber Cancer Inst & Harvard Medical School
Professor & Howard Hughes Medical Institute Investigator Charles
Rudin, M.D., Ph.D., Johns Hopkins: Sidney Kimmel Cancer Center
Director of Lung Cancer Therapeutics Program John
Minna, M.D., University of Texas Southwestern Medical Center at Dallas
Director of Hamon Center for Therapeutic Research
-
Broad expertise in biology and treatment of lung cancer
-
Experience in virotherapy field, with emphasis on use of tumor suppressor
genes
Daniel
Von Hoff, M.D., F.A.C.P. Arizona Cancer Center
Director of Cancer Therapeutics Program & Former President of AACR
-
Renowned expert in cancer biology and therapy, emphasis on pancreatic
cancer
-
Lead investigator in virotherapy (Onyx-015) trials
Vincent
Racaniello, Ph.D., Columbia University
Higgins Professor of Microbiology of Cancer
Mark A. McKinlay, Chief Scientific Officer, TetraLogic Pharmaceuticals
-
Co founder of ViroPharma Inc and TetraLogic Pharmaceuticals
-
Expert in development of antipicornaviral agents
-
Currently developing novel IAP antagonists for the treatment of cancer
|
